Business
Marizyme and Somahlution Announce Agreement with Leipzig Heart Center to Use DuraGraft in Patients undergoing Coronary Artery Bypass Surgery
Marizyme and Somahlution Announce Agreement with Leipzig Heart Center to Use DuraGraft in Patients undergoing Coronary Artery Bypass Surgery.
About this update from Marizyme, Inc.
[{"type":"text","content":"DuraGraft a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure.JUPITER, FL – April 8, 2020 – Marizyme (MRZM:OTCQB) and Somahlution, a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced that it received an agreement from Leipzig Heart Center in Germany to use the company’s flagship product, DuraGraft in CABG patients.Leipzig Heart Center, an internationally recognized leader in cardiac surgery that performs approximately 4000 CABG surgeries per year, is part of the ongoing “EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits with DuraGraft [VASC], to Evaluate the Safety and Performance of DuraGraft”. Based on promising outcomes observed in the registry, the Center will extend the registry to begin using DuraGraft in diabetic patients receiving at least one vein graft.We have seen encouraging evidence that reinforces the importance of appropriate graft treatment during surgery and the role of DuraGraft in improving outcomes and we are now interested in evaluating these effects in the diabetic patient population specifically,” said Dr. Martin Misfeld of Leipzig Heart Center.Patients with diabetes, in general, have worse clinical outcomes following CABG surgery and are more susceptible to adverse events following graft failure compared to non-diabetics and so there is much excitement regarding the use of DuraGraft in these patients.”The endothelial damage inhibitor DuraGraft has shown promising results in several preclinical studies and large-scale clinical investigations to adequately protect and preserve vascular conduits. Therefore, its use in diabetic CABG patients will provide further important data on its safety and potential to protect the grafts and improve clinical outcomes in this high-risk cohort of patients” said Dr. Maximilian Emmert from the German Heart Center Berlin, Germany and PI of the VASC Registry.Dr. Satish Chandran, CEO of Somahlution stated “We look forward to continuing in this important research with the Leipzig Heart Center and are extremely excited to offer this innovative technology to appropriate CABG patients for ...